The international phase 3 study of rivaroxaban versus standard anticoagulants for VTE in children has found similar efficacy and safety in the treatment arms. The study of almost 500 children, 0-17 years across 107 paediatric hospitals in 28 countries, found recurrent VTE in 1% of children treated for three months with rivaroxaban compared to 3% ...
‘A historic moment’: Prof Paul Monagle on the largest trial of anticoagulants in children
By Mardi Chapman
13 Nov 2019